Aptamer Group PLC (APTA) Earnings Call Transcripts

Aptamer Group PLC's Latest Earnings Call - March 30, 2026

Aptamer Group PLC reported its earnings for the six months ending December 31, 2025. Revenue increased by 27% to GBP 0.83 million, driven by strong contract signings with top pharma customers. The company reported an EBITDA loss of GBP 1 million, slightly improved from the prior period. Management highlighted the signing of two licensing deals in December 2025, expected to generate revenue in the second half of the fiscal year. The company raised GBP 4.275 million in March 2026 to fund AI/ML development and advance its therapeutic pipeline, extending its cash runway to Q2 2027. Guidance suggests continued revenue growth from licensing and fee-for-service contracts.

Reported metrics

Guidance from management

Management expects continued revenue growth from fee-for-service contracts and licensing deals. The recent fundraising extends the cash runway to Q2 2027 and supports strategic initiatives in AI/ML and therapeutic development.

What management said

Good afternoon. Thank you. So thank you for taking the time to listen to our results for the 6 months to the 31st of December 2025. I'll just skip through the obligatory disclaimer slides before coming on to an introduction. So I'll just introduce myself first. So I'm Arron. I'm Co-Founder of Aptamer Group. Founded the company in 2008. I have a PhD in structural biology and biophysics. And for my sins, I've run the c...

Good afternoon, everybody. I'm Andrew Rapson, CFO of Aptamer Group. I have over 20 years' experience now as a chartered accountant, joined Aptamer in August '22, and I have been CFO since August '23. And I've worked in the AIM environment now for just over 10 years.

What analysts pressed on

Analysts questioned the necessity of the recent capital raise given the existing cash runway to 2027. Concerns were also raised about the dilution impact of new share options and the alignment of management incentives with shareholder value.

Main topics on the call

• Revenue Growth — Revenue for the period was GBP 0.83 million, up 27% from the prior period, driven by strong contract signings in October and November. Management expects 70% of the GBP 2 million fee-for-service order book to be recogniz...
• Licensing Deals — Two licensing deals were signed in December 2025 with Twist Bioscience and Alphazyme, marking a significant step forward. These deals include upfront royalties and supply revenues, with orders already submitted post-peri...
• Cash Flow and Fundraising — Net cash outflow from operations was GBP 1.2 million, with a cash balance of GBP 1.5 million at period end. The company raised GBP 4.275 million in March 2026 to strengthen its market position and fund AI/ML development.
• AI/ML Development — The company plans to integrate its 15 years of discovery data into an AI/ML model to enhance its platform's capabilities. This initiative is seen as critical to maintaining competitive advantage in the fee-for-service sp...

Read the full Aptamer Group PLC transcript (March 30, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 13 Aptamer Group PLC earnings call transcripts on record, spanning March 14, 2023 to March 30, 2026. Based on this history, Aptamer Group PLC reports quarterly. The most recent call on file is dated March 30, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

APTA

Exchange

AIM

Country

GB

Sector

Health Care

Industry

Biotechnology

Calls on record

13

First call

March 14, 2023

Most recent

March 30, 2026

Reporting cadence

quarterly